Disease progression in HIV-infected patients treated with stavudine vs. zidovudine (Q44798388)

6 December 2017

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine (English)

1 reference

6 December 2017

1 reference

1

Amy C Justice

1 reference

6 December 2017

Daniel S Stein

2

1 reference

6 December 2017

Gregory P Fusco

3

1 reference

6 December 2017

Beth H Sherrill

4

1 reference

6 December 2017

Jennifer S Fusco

5

1 reference

6 December 2017

Susan C Danehower

6

1 reference

6 December 2017

Stephen L Becker

7

1 reference

6 December 2017

Nellie I Hansen

8

1 reference

6 December 2017

Neil M H Graham

9

1 reference

6 December 2017

CHORUS Program Team

10

1 reference

6 December 2017

1 January 2004

1 reference

Journal of Clinical Epidemiology

6 December 2017

1 reference

6 December 2017

57

1 reference

6 December 2017

1

1 reference

6 December 2017

89-97

1 reference

Mitochondrial myopathy caused by long-term zidovudine therapy

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Zidovudine: five years later

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Role of heme metabolism in AZT-induced bone marrow toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Hepatomegaly with severe steatosis in HIV-seropositive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Indinavir-associated lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Inborn and induced defects of mitochondria.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2803%2900245-2

7 January 2021

10.1016/S0895-4356(03)00245-2

Identifiers

DOI

1 reference

6 December 2017

1 reference